Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.63 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.60 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.60 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.60 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.60 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.60 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | RORA | P35398 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
| ▸ | RORB | Q92753 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14107129 | 0.98 | PSEN1 (0.62) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL551644 | 0.98 | PSEN1 (0.62) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9976723 | 0.98 | PSEN1 (0.62) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9905344 | 0.98 | PSEN1 (0.62) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL278343 | 0.93 | PGR (0.66) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14107127 | 0.91 | PSEN1 (0.59) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6275417 | 0.91 | PGR (0.64) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1001993 | 0.91 | PGR (0.64) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6278388 | 0.91 | PGR (0.64) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL750975 | 0.91 | PGR (0.64) | CNR2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088313-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2014-03-27 | — | — | US | disclosed |
| US-8609867-B2 | Substituted indolocarbazoles | XEROX CORPORATION (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-8110690-B2 | Substituted indolocarbazoles | XEROX CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2009-02-05 | — | — | US | disclosed |
| US-7456424-B2 | Thin film transistors including indolocarbozoles | XEROX CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060124923-A1 | Thin film transistors including indolocarbazoles | XEROX CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-20060125009-A1 | Thin film transistors including indolocarbazoles | XEROX CORPORATION | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | CNR2 240/4885PSEN1 3162/4885PSEN2 1766/4885 |
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | CNR2 240/4885PSEN1 3162/4885PSEN2 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.